11 completed. 4 Phase 1, 3 Phase 2, 2 Phase 3, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 2 | Completed 2 |
| Phase 4 | 2 | Completed 2 |
Follow Biothrax: new trials by email Literature Review of Biothrax trials Research Report on Biothrax
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults BW-1010: 50 µg - sprayer - IN, BW-1010: 50 µg - pipette - IN, BW-1010: 100 µg - sprayer - IN - Anthrax | Phase 1 | Completed | BlueWillow Biologics | 84 | 2020-01-08 | 2022-05-18 |
| VELOCITY: An Anthrax Vaccine Clinical Study AV7909, BioThrax - Anthrax | Phase 3 | Completed | Emergent BioSolutions | 3689 | 2019-03-11 | 2026-05-06 |
| BARDA Securing Anthrax Immunity For the Elderly BioThrax, AV7909, Sodium chloride injection USP, 0.9% (placebo) - Anthrax | Phase 2 | Completed | Biomedical Advanced Research and Development Authority | 305 | 2018-05-09 | 2020-07-21 |
| NasoShield Study of Safety and Immunogenicity NasoShield, BioThrax, Placebo - Healthy Volunteers | Phase 1 | Completed | Altimmune, Inc. | 145 | 2018-01-18 | 2025-06-24 |
| A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines AVA, Ad4-PA-1, Ad4-PA-GPI-1 - Anthrax Infection | Phase 1 | Completed | Emergent BioSolutions | 120 | 2013-11-01 | 2024-03-18 |
| A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels AV7909, BioThrax - Anthrax | Phase 2 | Completed | Emergent BioSolutions | 168 | 2013-01-01 | 2024-03-18 |
| Ciprofloxacin BioThrax Co-Administration Study BioThrax, Ciprofloxacin - Anthrax | Phase 2 | Completed | Emergent BioSolutions | 154 | 2012-12-01 | 2025-06-15 |
| Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule BioThrax® - Bacillus Anthracis (Anthrax) | Phase 4 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 328 | 2012-07-01 | 2014-05-28 |
| Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults BioThrax - Anthrax | Phase 3 | Completed | Emergent BioSolutions | 200 | 2011-11-01 | 2024-04-09 |
| Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults BioThrax, AV7909 Formulation 1, AV7909 Formulation 2 - Bacillus Anthracis (Anthrax) Infection | Phase 1 | Completed | Emergent BioSolutions | 105 | 2010-12-01 | 2024-03-18 |
| Anthrax Vaccine Clinical Trial to Assess Dose Reduction and Route Change Anthrax Vaccine Adsorbed, Saline injection - Healthy | Phase 4 | Completed | Centers for Disease Control and Prevention | 1564 | 2002-05-01 | 2024-05-29 |
Anthrax (11) · Bacillaceae Infections (1) · Bacterial Infections (1) · Gram-Positive Bacterial Infections (1) · Infections (1)
Emergent BioSolutions (6) · Altimmune, Inc. (1) · Biomedical Advanced Research and Development Authority (1) · BlueWillow Biologics (1) · Centers for Disease Control and Prevention (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (11)
Robert Hopkins, MD, MPH, TM (2) · Carlos Fierro, MD (1) · Cynthia Strout, MD (1) · Derek Muse, MD (1) · Edward Bernton, MD (1) · Emanuel DeNoia, MD (1) · Gideon Akintunde, MD (1) · Gurdyal Kalsi, MD, MTOPRA (1) · Jakub Simon, MD (1) · Jennifer Wright, DVM (1) · Marc Gurwith, MD (1) · Mo Elsafy, MD, MSc (1) · Stephan Sharp, MD (1)
PMID 21368772, PMID 23701746, PMID 23741398, PMID 24373307, PMID 26865594, PMID 33129609, PMID 38352727, PMID 41401704